Bone morphogenetic protein 7 suppresses the progression of hepatic fibrosis and regulates the expression of gremlin and transforming growth factor β1

Molecular Medicine Reports

Volumn 6, Issue 1, 2012, Pages 246-252

  Yang, Tao ^a   Chen, Shao Long ^a   Lu, Xiao Ju ^a   Shen, Chun Yan ^a   Liu, Yan ^a   Chen, Yong Ping ^a  

^a WENZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Bone morphogenetic protein 7; Gremlin; Hepatic fibrosis; Transforming growth factor 1

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; COLLAGEN TYPE 1; GELATINASE A; GREMLIN PROTEIN; RECOMBINANT OSTEOGENIC PROTEIN 1; REGULATOR PROTEIN; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFECT; LIVER FIBROSIS; MALE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; TREATMENT OUTCOME;

ANIMALS; BONE MORPHOGENETIC PROTEIN 7; CHEMOKINE CCL4; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; GENE EXPRESSION REGULATION; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LIVER CIRRHOSIS; MICE; MICE, INBRED C57BL; TRANSFORMING GROWTH FACTOR BETA;

EID: 84861613451     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2012.892     Document Type: Article

References (26)

1. Schuppan D and Afdhal NH: Liver cirrhosis. Lancet 371: 838-851, 2008. (Pubitemid 351323895)
2. Friedman SL: Evolving challenges in hepatic fibrosis. Nat Rev Gastroenterol Hepatol 7: 425-436, 2010.
3. Tsukada S, Parsons CJ and Rippe RA: Mechanisms of liver fibrosis. Clin Chim Acta 364: 33-60, 2006. (Pubitemid 43120627)
4. Friedman SL and Bansal MB: Reversal of hepatic fibrosis - fact or fantasy? Hepatology 43: S82-S88, 2006.
5. Mann DA and Mann J: Epigenetic regulation of hepatic stellate cell activation. J Gastroenterol Hepatol 23 (Suppl 1): 108-111, 2008.
6. Ghiassi-Nejad Z and Friedman SL: Advances in antifibrotic therapy. Expert Rev Gastroenterol Hepatol 2: 803-816, 2008.
7. Senoo H, Yoshikawa K, Morii M, Miura M, Imai K and Mezaki Y: Hepatic stellate cell (vitamin A-storing cell) and its relative - past, present and future. Cell Biol Int 34: 1247-1272, 2010.
8. Yu FJ, Dong PH, Fan XF, Lin Z, Chen YP and Li J: Down-regulation of angiotensin II by shRNA reduces collagen synthesis in hepatic stellate cells. Int J Mol Med 25: 801-806, 2010.
9. Meyer C, Meindl-Beinker NM and Dooley S: TGF-beta signaling in alcohol induced hepatic injury. Front Biosci 15: 740-749, 2010.
10. Giannelli G, Mazzocca A, Fransvea E, Lahn M and Antonaci S: Inhibiting TGF-beta signaling in hepatocellular carcinoma. Biochim Biophys Acta 1815: 214-223, 2011.
11. De Bleser PJ, Niki T, Rogiers V and Geerts A: Transforming growth factor-beta gene expression in normal and fibrotic rat liver. J Hepatol 26: 886-893, 1997. (Pubitemid 27145714)
12. Inagaki Y and Okazaki I: Emerging insights into transforming growth factor beta Smad signal in hepatic fibrogenesis. Gut 56: 284-292, 2007.
13. Hong SW, Jung KH, Lee HS, et al: Suppression by fucoidan of liver fibrogenesis via the TGF-beta/Smad pathway in protecting against oxidative stress. Biosci Biotechnol Biochem 75: 833-840, 2011.
14. Sadick H, Herberger A, Riedel K, et al: TGF-beta1 antisense therapy modulates expression of matrix metalloproteinases in keloid-derived fibroblasts. Int J Mol Med 22: 55-60, 2008.
15. Soderberg SS, Karlsson G and Karlsson S: Complex and context dependent regulation of hematopoiesis by TGF-beta superfamily signaling. Ann NY Acad Sci 1176: 55-69, 2009.
16. Massague J: How cells read TGF-beta signals. Nat Rev Mol Cell Biol 1: 169-178, 2000.
17. Derynck R and Zhang YE: Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature 425: 577-584, 2003. (Pubitemid 37280136)
18. Zeisberg M, Hanai J, Sugimoto H, et al: BMP-7 counteracts TGF-beta1-induced epithelial-to-mesenchymal transition and reverses chronic renal injury. Nat Med 9: 964-968, 2003. (Pubitemid 36889942)
19. Zeisberg M and Kalluri R: Reversal of experimental renal fibrosis by BMP7 provides insights into novel therapeutic strategies for chronic kidney disease. Pediatr Nephrol 23: 1395-1398, 2008.
20. Claesson-Welsh L: gremlin: vexing VEGF receptor agonist. Blood 116: 3386-3387, 2010.
21. Carvajal G, Droguett A, Burgos ME, et al: gremlin: a novel mediator of epithelial mesenchymal transition and fibrosis in chronic allograft nephropathy. Transplant Proc 40: 734-739, 2008. (Pubitemid 351608666)
22. Shen H, Huang G, Hadi M, et al: Transforming growth factor-beta1 downregulation of Smad1 gene expression in rat hepatic stellate cells. Am J Physiol Gastrointest Liver Physiol 285: G539-G546, 2003. (Pubitemid 37021813)
23. Weiskirchen R, Meurer SK, Gressner OA, Herrmann J, Borkham-Kamphorst E and Gressner AM: BMP-7 as antagonist of organ fibrosis. Front Biosci 14: 4992-5012, 2009.
24. Tacke F, Gabele E, Bataille F, et al: Bone morphogenetic protein 7 is elevated in patients with chronic liver disease and exerts fibrogenic effects on human hepatic stellate cells. Dig Dis Sci 52: 3404-3415, 2007. (Pubitemid 350077191)
25. Koli K, Myllarniemi M, Vuorinen K, et al: Bone morphogenetic protein-4 inhibitor gremlin is overexpressed in idiopathic pulmonary fibrosis. Am J Pathol 169: 61-71, 2006.
26. Boers W, Aarrass S, Linthorst C, Pinzani M, Elferink RO and Bosma P: Transcriptional profiling reveals novel markers of liver fibrogenesis: gremlin and insulin-like growth factor-binding proteins. J Biol Chem 281: 16289-16295, 2006.